Agency Forms Undergoing Paperwork Reduction Act Review, 63924-63925 [2011-26595]
Download as PDF
<![CDATA[
63924
Federal Register / Vol. 76, No. 199 / Friday, October 14, 2011 / Notices
authorization and appropriation of
availability of funds, GSA control of the
site to complete archaeological
investigations and continuity of the
tenant agencies’ Program of
Requirements as they were understood
at the time this study was completed.
Following this thirty (30) day notice
in the Federal Register, the GSA will
issue a ROD at which time its
availability will be announced in the
Federal Register and local media.
II. Distribution
Copies of the FEIS are being
distributed to select stakeholders as well
as being made available for public
review at the International Falls Public
Library, Chamber of Commerce Offices,
and Koochiching County Office
Building.
Dated: October 6, 2011.
Ann P. Kalayil,
Regional Commissioner, Public Buildings
Service, Great Lakes Region.
[FR Doc. 2011–26647 Filed 10–13–11; 8:45 am]
BILLING CODE 6820–A9–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration on Aging
Agency Information Collection
Activities; Proposed Collection;
Comment Request; the Evaluation of
the Aging and Disability Resource
Center Program
Administration on Aging, HHS.
Notice.
AGENCY:
ACTION:
The Administration on Aging
(AoA) is announcing an opportunity for
public comment on the proposed
collection of certain information by the
agency. Under the Paperwork Reduction
Act of 1995 (the PRA), Federal agencies
are required to publish notice in the
Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information, and
to allow 60 days for public comment in
response to the notice. This notice
solicits comments on the information
collection requirements relating to the
Evaluation of the Aging and Disability
Resource Center Program.
DATES: Submit written or electronic
comments on the collection of
information by December 13, 2011.
ADDRESSES: Submit electronic
comments on the collection of
information to: Susan Jenkins at
Susan.Jenkins@aoa.hhs.gov.
Submit written comments on the
collection of information to
tkelley on DSK3SPTVN1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
15:20 Oct 13, 2011
Jkt 226001
Administration on Aging, Washington,
DC 20201, Attn. Susan Jenkins.
FOR FURTHER INFORMATION CONTACT:
Susan Jenkins at 202.357.3591.
SUPPLEMENTARY INFORMATION: Under the
PRA (44 U.S.C. 3501–3520), Federal
agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency request
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44
U.S.C. 3506(c)(2)(A)) requires Federal
agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information,
before submitting the collection to OMB
for approval. To comply with this
requirement, AoA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following collection
of information, AoA invites comments
on: (1) Whether the proposed collection
of information is necessary for the
proper performance of AoA’s functions,
including whether the information will
have practical utility; (2) the accuracy of
AoA’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used; (3)
ways to enhance the quality, utility, and
clarity of the information to be
collected; and (4) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
when appropriate, and other forms of
information technology. The Aging and
Disability Resource Center (ADRC)
Program is a collaborative effort of the
Administration on Aging (AoA) and the
Centers for Medicare & Medicaid
Services (CMS). ADRCs target services
to the elderly and individuals with
physical disabilities, serious mental
illness, and/or developmental/
intellectual disabilities. The ultimate
goal of the ADRCs is to serve all
individuals with long-term care needs
regardless of their age or disability. The
statutory authority for the ADRC grant
program is contained in Titles II and IV
of the Older Americans Act (OAA) (42
U.S.C. 3032), as amended by the Older
Americans Act Amendments of 2006,
Public Law 109–365. (Catalog of Federal
Domestic Assistance 93.048, Title IV
Discretionary Projects). 42 U.S.C. 3017
specifies that the Assistant Secretary for
PO 00000
Frm 00024
Fmt 4703
Sfmt 4703
Aging ‘‘shall measure and evaluate the
impact of all programs authorized by
this chapter * * * Evaluations shall be
conducted by persons not immediately
involved in the administration of the
program or project evaluated.’’ This new
collection of information is necessary to
determine the overall effect of ADRCs
on both long term support and service
systems and individuals. AoA will
gather information about how ADRCs
provide services and whether
consumers, who access ADRCs, as
compared to consumers who access
other systems, report that the experience
is more personalized, consumerfriendly, streamlined, and efficient. Staff
of the Administration on Aging’s Office
of Program Innovation and
Demonstration will use the information
to both determine the value of the ADRC
model and to improve program
operations. The evaluation will include
both process and outcome components.
The Agency Data Collection Tool
requests respondents’ names and
contact information to allow the
research team to contact potential
respondents. The Personal Experience
Survey will collect information about
consumers’ level and type of disability,
and demographic characteristics
including race and living status.
Respondents will be asked to provide
their Medicare and/or Medicaid
identification numbers to allow for
analysis of the effect of the ADRC
program on heath care utilization and
nursing home diversion. The proposed
data collection tools may be found on
the AoA Web site: [INSERT WEB
ADDRESS WHEN DETERMINED]. AoA
estimates the burden of this collection at
1,732 hours for individuals and 1,294
hours for organizations—Total Burden
for Study 3,026.
Dated: October 7, 2011.
Kathy Greenlee,
Assistant Secretary for Aging.
[FR Doc. 2011–26552 Filed 10–13–11; 8:45 am]
BILLING CODE 4154–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30 Day–12–0773]
Agency Forms Undergoing Paperwork
Reduction Act Review
The Centers for Disease Control and
Prevention (CDC) publishes a list of
information collection requests under
review by the Office of Management and
Budget (OMB) in compliance with the
E:\FR\FM\14OCN1.SGM
14OCN1
63925
Federal Register / Vol. 76, No. 199 / Friday, October 14, 2011 / Notices
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
requests, call the CDC Reports Clearance
Officer at (404) 639–5960 or send an email to omb@cdc.gov. Send written
comments to CDC Desk Officer, Office of
Management and Budget, Washington,
DC or by fax to (202) 395–5806. Written
comments should be received within 30
days of this notice.
Proposed Project
National Surveillance for Severe
Adverse Events Associated with
Treatment of Latent Tuberculosis
Infection (NSSAE)—Reinstatement with
change—Division of Tuberculosis
Elimination (DTBE), National Center for
HIV/AIDS, Viral Hepatitis, STD, and TB
Prevention (NCHHSTP), Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
Between October 2000 and September
2004, the CDC received reports of 50
patients with severe adverse events
(SAEs) associated with the use of the
two or three-month regimen of rifampin
and pyrazinamide (RZ) for the treatment
of LTBI; 12 (24%) patients died
(Morbidity and Mortality Weekly Report
2003;52[31]:735–9). In 2004, CDC began
collecting reports of SAEs associated
with any treatment regimen for LTBI.
For surveillance purposes, an SAE was
Puerto Rico, and 7 jurisdictions in the
Pacific and Caribbean). Data will be
collected using the data collection form
for adverse event associated with LTBI
treatment (NSSAE). The NSSAE form is
completed for each reported
hospitalization or death related to
treatment of LTBI and contains
demographic, clinical, and laboratory
information. CDC will analyze and
periodically publish reports
summarizing national LTBI treatment
adverse events statistics and also will
conduct special analyses for publication
in peer-reviewed scientific journals to
further describe and interpret these
data.
The Food and Drug Administration
(FDA) collects data on adverse events
related to drugs through the FDA
MedWatch Program. CDC is
collaborating with FDA in the reporting
of SAEs. Reporting will be conducted
through telephone, e-mail, or during
CDC site visits. In this request, CDC is
requesting approval for approximately
60 burden hours annually, an estimated
increase of 36 hours from the previously
approved 24 hours. This is due to an
estimated increase of reports of SAEs
after the publication of the MMWR
report on SAEs in 2010. There are no
costs to respondents other than their
time to gather medical records to
complete the reporting form.
defined as any drug-associated reaction
resulting in a patient’s hospitalization or
death after at least one treatment dose
for LTBI. During 2004–2008, CDC
received 17 reports of SAEs in 15 adults
and two children; all patients had
received isoniazid (INH) and had
experienced severe liver injury
(Morbidity and Mortality Weekly Report
2010; 59:224–9).
The CDC requests approval for a 3year reinstatement with change of the
previously approved National
Surveillance for Severe Adverse Events
Associated with Treatment of Latent
Tuberculosis Infection (OMB No. 0920–
0773, expired April 31, 2011). The
changes include a shortened data
collection form and an increase in the
number of respondents. This project
will continue the passive reporting
system for SAEs associated with therapy
for LTBI. The system will rely on
medical chart review and/or onsite
investigations by TB control staff.
The purpose of this information
collection request is to determine the
annual number and trends of SAEs
associated with treatment of LTBI and
identify common characteristics of
patients with SAEs during treatment of
LTBI. Potential correspondents are any
of the 60 reporting areas for the national
TB surveillance system (the 50 states,
the District of Columbia, New York City,
ESTIMATE OF ANNUALIZED BURDEN HOURS
Number of
respondents
Type of respondents
Physicians ....................................................................................................................................
Nurses ..........................................................................................................................................
Medical Clerk ...............................................................................................................................
Dated: October 7, 2011.
Daniel Holcomb,
Reports Clearance Officer, Centers for Disease
Control and Prevention.
[FR Doc. 2011–26595 Filed 10–13–11; 8:45 am]
BILLING CODE P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
tkelley on DSK3SPTVN1PROD with NOTICES
Centers for Disease Control and
Prevention
Proposed Project
[30Day-12-11JJ]
Agency Forms Undergoing Paperwork
Reduction Act Review
The Centers for Disease Control and
Prevention (CDC) publishes a list of
information collection requests under
VerDate Mar<15>2010
17:41 Oct 13, 2011
Jkt 226001
review by the Office of Management and
Budget (OMB) in compliance with the
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
requests, call the CDC Reports Clearance
Officer at (404) 639–5960 or send an email to omb@cdc.gov. Send written
comments to CDC Desk Officer, Office of
Management and Budget, Washington,
DC 20503 or by fax to (202) 395–5806.
Written comments should be received
within 30 days of this notice.
Evaluating Locally-Developed HIV
Prevention Interventions for AfricanAmerican MSM in Los Angeles—New—
National Center for HIV/AIDS, Viral
Hepatitis, STD, TB Prevention
(NCHHSTP), Centers for Disease Control
and Prevention (CDC).
PO 00000
Frm 00025
Fmt 4703
Sfmt 4703
10
10
10
Number of
responses per
respondent
1
1
1
Average
burden per
response
(in hours)
1
4
1
Background and Brief Description
Data on HIV cases reported in 33 U.S.
states with HIV reporting indicate the
burden of HIV/AIDS is most
concentrated in the African American
population compared to other racial/
ethnic groups. Of the 49,704 African
American males diagnosed with HIV
between 2001 and 2004, 54% of these
cases were among men who have sex
with men (MSM). In Los Angeles
County (LAC), the proportion of HIV/
AIDS cases among African American
males attributable to male-to-male
sexual transmission is even greater
(75%). In the absence of an effective
vaccine, behavioral interventions
represent one of the few methods for
reducing high HIV incidence among
African American MSM (AAMSM).
Unfortunately, in the third decade of the
E:\FR\FM\14OCN1.SGM
14OCN1
]]>Agencies
[Federal Register Volume 76, Number 199 (Friday, October 14, 2011)]
[Notices]
[Pages 63924-63925]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-26595]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30 Day-12-0773]
Agency Forms Undergoing Paperwork Reduction Act Review
The Centers for Disease Control and Prevention (CDC) publishes a
list of information collection requests under review by the Office of
Management and Budget (OMB) in compliance with the
[[Page 63925]]
Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of
these requests, call the CDC Reports Clearance Officer at (404) 639-
5960 or send an e-mail to omb@cdc.gov. Send written comments to CDC
Desk Officer, Office of Management and Budget, Washington, DC or by fax
to (202) 395-5806. Written comments should be received within 30 days
of this notice.
Proposed Project
National Surveillance for Severe Adverse Events Associated with
Treatment of Latent Tuberculosis Infection (NSSAE)--Reinstatement with
change--Division of Tuberculosis Elimination (DTBE), National Center
for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP),
Centers for Disease Control and Prevention (CDC).
Background and Brief Description
Between October 2000 and September 2004, the CDC received reports
of 50 patients with severe adverse events (SAEs) associated with the
use of the two or three-month regimen of rifampin and pyrazinamide (RZ)
for the treatment of LTBI; 12 (24%) patients died (Morbidity and
Mortality Weekly Report 2003;52[31]:735-9). In 2004, CDC began
collecting reports of SAEs associated with any treatment regimen for
LTBI. For surveillance purposes, an SAE was defined as any drug-
associated reaction resulting in a patient's hospitalization or death
after at least one treatment dose for LTBI. During 2004-2008, CDC
received 17 reports of SAEs in 15 adults and two children; all patients
had received isoniazid (INH) and had experienced severe liver injury
(Morbidity and Mortality Weekly Report 2010; 59:224-9).
The CDC requests approval for a 3-year reinstatement with change of
the previously approved National Surveillance for Severe Adverse Events
Associated with Treatment of Latent Tuberculosis Infection (OMB No.
0920-0773, expired April 31, 2011). The changes include a shortened
data collection form and an increase in the number of respondents. This
project will continue the passive reporting system for SAEs associated
with therapy for LTBI. The system will rely on medical chart review
and/or onsite investigations by TB control staff.
The purpose of this information collection request is to determine
the annual number and trends of SAEs associated with treatment of LTBI
and identify common characteristics of patients with SAEs during
treatment of LTBI. Potential correspondents are any of the 60 reporting
areas for the national TB surveillance system (the 50 states, the
District of Columbia, New York City, Puerto Rico, and 7 jurisdictions
in the Pacific and Caribbean). Data will be collected using the data
collection form for adverse event associated with LTBI treatment
(NSSAE). The NSSAE form is completed for each reported hospitalization
or death related to treatment of LTBI and contains demographic,
clinical, and laboratory information. CDC will analyze and periodically
publish reports summarizing national LTBI treatment adverse events
statistics and also will conduct special analyses for publication in
peer-reviewed scientific journals to further describe and interpret
these data.
The Food and Drug Administration (FDA) collects data on adverse
events related to drugs through the FDA MedWatch Program. CDC is
collaborating with FDA in the reporting of SAEs. Reporting will be
conducted through telephone, e-mail, or during CDC site visits. In this
request, CDC is requesting approval for approximately 60 burden hours
annually, an estimated increase of 36 hours from the previously
approved 24 hours. This is due to an estimated increase of reports of
SAEs after the publication of the MMWR report on SAEs in 2010. There
are no costs to respondents other than their time to gather medical
records to complete the reporting form.
Estimate of Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of burden per
Type of respondents respondents responses per response (in
respondent hours)
----------------------------------------------------------------------------------------------------------------
Physicians...................................................... 10 1 1
Nurses.......................................................... 10 1 4
Medical Clerk................................................... 10 1 1
----------------------------------------------------------------------------------------------------------------
Dated: October 7, 2011.
Daniel Holcomb,
Reports Clearance Officer, Centers for Disease Control and Prevention.
[FR Doc. 2011-26595 Filed 10-13-11; 8:45 am]
BILLING CODE P
